Lu-NeoB

Phase 2Small molecule

Lu-NeoB is one of 85 small molecule programs targeting Metastatic Neuroendocrine Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Neuroendocrine Prostate CancerActive, not recruiting

GlioblastomaActive, not recruiting

Breast CancerActive, not recruiting

Metastatic Neuroendocrine Prostate CancerPhase 1

Active, not recruiting

GlioblastomaPhase 1

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lu-NeoB

Novartis

Phase 2

2 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Spravato

WWim Janssens

Preclinical

2 4

Duragesic

CCephalon

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 7

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 8

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 9

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 10

Bisphosphonate

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalActive, not recruiting

Breast Cancer

NCT06247995

Q2 2032

Phase 1Active, not recruiting

Breast Cancer

NCT05870579

Q3 2032

Phase 1Active, not recruiting

Glioblastoma

NCT05739942

Clinical

Trials by Indication[1]

Breast Cancer2 trials

A Phase I/II, Open-label, Multi-center Trial of [177Lu]Lu-NeoB in Combination With Capecitabine in Adult Patients With Gastrin Releasing Peptide Receptor Positive, Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Active, not recruiting· Novartis logo

Novartis·Preclinical·NCT06247995·20 enrolled

A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative and Gastrin Releasing Peptide Receptor Positive Advanced Breast Cancer Experiencing Early Relapse From (Neo)Adjuvant Endocrine Therapy or Who Have Progressed on Endocrine Therapy in Combination With a CDK4/6 Inhibitor for Advanced Disease

Active, not recruiting· Novartis logo

Novartis·Phase 1·NCT05870579·28 enrolled

Glioblastoma1 trial

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Active, not recruiting· Novartis logo

Novartis·Phase 1·NCT05739942·40 enrolled

Metastatic Neuroendocrine Prostate Cancer1 trial

A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruiting· Novartis logo

Novartis·Phase 1·NCT06379217·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Lu-NeoB. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lu-NeoB compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lu-NeoB. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

Lu-NeoB

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2032

Q3 2032

Trials by Indication[1]

Breast Cancer2 trials

Glioblastoma1 trial

Metastatic Neuroendocrine Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News